Searched for
BETA DRUGS FUNDING
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Stock picks of the week; 5 stocks with consistent score improvement and upside potential of up to 25%Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 27% in 1 yearAfter the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 22%As the market grappled with confusion over the Strait of Hormuz, there was more trouble for the bulls. After a few days of respite, another...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsHas a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Beta Drugs raises Rs 117 crore from HealthQuadBeta Drugs secured Rs 117 crore from HealthQuad and other investors to expand globally and boost operational capabilities. The oncology-foc...
- Ashish Kacholia offloads nearly 4 lakh shares of this smallcap manufacturing companyAce investor Ashish Kacholia made a move on Tuesday by selling a portion of his stake in Ador Welding, a small-cap manufacturer renowned fo...
- Ashish Kacholia picks up 17% stake in largest homegrown burger chain JumbokingAce investor Ashish Kacholia has picked up a 17.2% stake in homegrown burger chain Jumboking for an undisclosed amount, becoming its second...
- IT, pharma and telecom top sectoral picks for MFs in AprilFund managers have been sellers in select public sector companies.
- Breakthrough using atomic science can treat Alzheimer'sLondon, July 6 (IANS) British researchers have succeeded in revealing the atomic structure of one of the abnormal filaments that lead to Al...
- AstraZeneca sells ageing beta-blocker to Recordati for $300 mlnAstraZeneca, which retains rights to the beta-blocker outside Europe, will continue to manufacture and ship product to Recordati under a su...
- Ex-J&J India head led fight against patentCancer Patients Aid Association is ironically headed by a former country head of a multi-national medical products company.
- Rel Life Sciences to focus on R&D, for nowThe company is all set to launch fifth biosimilar drug and seeks approvals for clinical trials and stem-cell treatment.
- Wanbury acquires Spanish drugmaker for Rs 240 crWanbury on Monday said it has agreed to acquire Spanish drugmaker Industria Farmaceutica Cantabri’s branded generic business for Rs 240 cro...
Load More
